Fig. 3
Comparison of HLA-A2 AAD transgenic mice vaccinated with CRT/E7 or CRT/E7(N53S) on their ability to generate murine H-2Db restricted E7 peptide (aa49-57)-specific or HLA-A2 restricted E7 peptide (aa11-20)-specific CD8 + T cell immune response. Healthy HLA-A2 (AAD) transgenic mice (5 per group) were injected with either CRT/E7 or CRT/E7(N53S). The DNA vaccines were delivered to the shaved leg region of mice through intramuscular injection followed by electroporation (10 µg/plasmid, 30 µl/injection). Vaccines were injected twice a week for two consecutive weeks. One week after final vaccination, PBMCs from vaccinated mice were isolated and stained for CD8 + E7 peptide (aa11-20) loaded HLA-A2 tetramer + or E7 peptide (aa49-57) loaded H-2Db tetramer + T cells and analyzed by flow cytometry analysis. A Representative flow cytometry analysis of PBMCs. The percentage of E7 peptide (aa49-57) loaded- H-2Db tetramer positive T cells is shown in the number above the box. B Vertical scatter plot summarizing the data derived from E7 peptide (aa49-57)-loaded H-2Db tetramer and CD8 + staining from mice vaccinated with CRT/E7 or CRT/E7(N53S) DNA. C Representative flow cytometry analysis of PBMCs. The percentage of E7 peptide (aa11-20) loaded- HLA-A2 tetramer positive T cells is shown in the number above the box. D Vertical scatter plot summarizing the data derived from E7 peptide (aa11-20)-loaded HLA-A2 tetramer and CD8 + staining from mice vaccinated with CRT/E7 or CRT/E7(N53S)